Antibody Drug Conjugates Contract Manufacturing Global Market Report 2024

Description

Antibody-drug conjugates (ADC) contract manufacturing involves outsourcing the production of these specialized biopharmaceuticals to contract development and manufacturing organizations (CDMOs). ADCs are intricate compounds that merge an antibody with a cytotoxic drug, specifically designed to target and eliminate certain cancer cells while reducing harm to healthy cells.

The primary types of ADC contract manufacturing include immunoglobulin G1 (IgG1) and immunoglobulin G4 (IgG4). IgG1 is one of the four subclasses of immunoglobulin G, which is an antibody present in blood and extracellular fluid. Various types of linkers used in ADCs include cleavable linkers and non-cleavable linkers, which are employed for conditions such as myeloma, lymphoma, and breast cancer, among others, and are utilized in different phases, including clinical and commercial production.

The antibody-drug conjugates contract manufacturing market research report is one of a series of new reports from The Business Research Company that provides antibody-drug conjugates contract manufacturing market statistics, including antibody-drug conjugates contract manufacturing industry global market size, regional shares, competitors with an antibody-drug conjugates contract manufacturing market share, detailed antibody-drug conjugates contract manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the antibody-drug conjugates contract manufacturing industry. This antibody-drug conjugates contract manufacturing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antibody drug conjugates contract manufacturing market size has grown strongly in recent years. It will grow from $8.72 billion in 2023 to $9.57 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be linked to the rising incidence of cancer, an increased demand for targeted therapies, advancements in antibody-drug conjugates, higher investments in research and development, regulatory approvals for new ADCs, and the expansion of pharmaceutical companies.

The antibody drug conjugates contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $14.00 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The growth anticipated during the forecast period is driven by the expected rise of personalized medicine, expanding uses of antibody-drug conjugates (ADCs) beyond oncology, increasing partnerships between biotech and pharmaceutical companies, a greater adoption of ADCs in clinical trials, and a growing focus on cost-effective manufacturing solutions. Key trends expected in this period include progress in biomarker identification, advancements in biotechnology, a higher adoption of next-generation ADC technologies, improvements in linker and payload technologies, and the integration of artificial intelligence in drug development.

The expanding biopharmaceutical industry is anticipated to drive the growth of the antibody-drug conjugates (ADCs) contract manufacturing market in the future. This industry is centered on the development, production, and commercialization of drugs derived from biological sources, employing biotechnology and molecular biology to create innovative therapies and treatments. Factors contributing to the growth of the biopharmaceutical sector include rapid advancements in biotechnology, increasing demand for personalized medicine, and rising investments in research and development aimed at new therapies. ADCs contract manufacturing plays a crucial role in supporting the biopharmaceutical industry by providing specialized production services that facilitate the development and commercialization of these advanced therapies. This allows biopharmaceutical companies to efficiently scale up production while maintaining high-quality standards, enabling them to focus on their primary research and development efforts. For example, in May 2024, the Department of Health and Social Care, a UK government agency, reported that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue for the year 2021/22, which represented 43% of the entire life sciences industry. Consequently, the growth of the biopharmaceutical sector is propelling the antibody-drug conjugates contract manufacturing market forward.

Key players in the antibody-drug conjugates contract manufacturing market are concentrating on creating innovative solutions, such as single-use reactors, to improve production flexibility, minimize contamination risks, and streamline the manufacturing process, ultimately enhancing the efficiency and scalability of ADC production. Single-use reactors are transforming ADC contract manufacturing by providing a flexible, efficient, and contamination-free option for producing these complex biologics. For instance, in September 2024, MilliporeSigma, a US-based life science company, introduced the Mobius ADC Reactor, designed specifically for the efficient manufacturing of antibody-drug conjugates. This reactor incorporates advanced mixing and control technologies that facilitate conjugation, enhance scalability, and improve consistency. The Mobius ADC Reactor supports higher yields and better quality control in ADC production, catering to the increasing demand for targeted cancer therapies that offer improved safety and efficacy.

In March 2024, Johnson & Johnson, a US-based corporation involved in pharmaceuticals, biotechnology, and medical technologies, acquired Ambrx Biopharma Inc. for $2.0 billion. This acquisition aims to strengthen Johnson & Johnson's portfolio of advanced therapies by incorporating Ambrx's innovative drug development technologies and enhancing its capabilities in biologics and targeted treatments. Ambrx Biopharma Inc. is a US-based biotechnology company dedicated to developing cutting-edge therapies, including antibody-drug conjugates (ADCs).

Major companies operating in the antibody drug conjugates contract manufacturing market are AbbVie Inc., Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Boehringer Ingelheim, Recipharm AB, Sigma-Aldrich, Sartorius AG, Curia, Lonza Group AG, Catalent Inc., KBI Biopharma, Alcami Corporation, Formosa Laboratories, BioVectra Inc., Axplora, Abzena PLC, ImmunoGen Inc., EirGenix Inc., Avid Bioservices Inc., Mersana Therapeutics, Cerbios-Pharma SA, Creative Biolabs, Aurigene Pharmaceutical Services Ltd., Sterling Pharma Solutions

North America was the largest region in the antibody drug conjugates contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody drug conjugates contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibody drug conjugates contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibody drug conjugates contract manufacturing market includes revenues earned by entities by providing process development, scale-up and manufacturing, analytical testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibody Drug Conjugates Contract Manufacturing Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibody drug conjugates contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibody drug conjugates contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibody drug conjugates contract manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Immunoglobulin G1(Igg1); Immunoglobulin G4(Igg4)
2) By Linker: Cleavable Linker; Non-Cleavable Linker
3) By Condition: Myeloma; Lymphoma; Breast Cancer; Other Conditions
4) By Phase: Clinical; Commercial
Companies Mentioned: AbbVie Inc.; Eli Lilly and Company; Gilead Sciences Inc.; Merck KGaA; Boehringer Ingelheim
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r20128

1. Executive Summary

2. Antibody Drug Conjugates Contract Manufacturing Market Characteristics

3. Antibody Drug Conjugates Contract Manufacturing Market Trends And Strategies

4. Antibody Drug Conjugates Contract Manufacturing Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Antibody Drug Conjugates Contract Manufacturing Market Size and Growth

5.1. Global Antibody Drug Conjugates Contract Manufacturing Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Antibody Drug Conjugates Contract Manufacturing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Antibody Drug Conjugates Contract Manufacturing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antibody Drug Conjugates Contract Manufacturing Market Segmentation

6.1. Global Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Immunoglobulin G1(Igg1)
Immunoglobulin G4(Igg4)
6.2. Global Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Cleavable Linker
Non-Cleavable Linker
6.3. Global Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Myeloma
Lymphoma
Breast Cancer
Other Conditions
6.4. Global Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Clinical
Commercial

7. Antibody Drug Conjugates Contract Manufacturing Market Regional And Country Analysis

7.1. Global Antibody Drug Conjugates Contract Manufacturing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Antibody Drug Conjugates Contract Manufacturing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market

8.1. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antibody Drug Conjugates Contract Manufacturing Market

9.1. China Antibody Drug Conjugates Contract Manufacturing Market Overview
9.2. China Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antibody Drug Conjugates Contract Manufacturing Market

10.1. India Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antibody Drug Conjugates Contract Manufacturing Market

11.1. Japan Antibody Drug Conjugates Contract Manufacturing Market Overview
11.2. Japan Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antibody Drug Conjugates Contract Manufacturing Market

12.1. Australia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antibody Drug Conjugates Contract Manufacturing Market

13.1. Indonesia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antibody Drug Conjugates Contract Manufacturing Market

14.1. South Korea Antibody Drug Conjugates Contract Manufacturing Market Overview
14.2. South Korea Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antibody Drug Conjugates Contract Manufacturing Market

15.1. Western Europe Antibody Drug Conjugates Contract Manufacturing Market Overview
15.2. Western Europe Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antibody Drug Conjugates Contract Manufacturing Market

16.1. UK Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antibody Drug Conjugates Contract Manufacturing Market

17.1. Germany Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antibody Drug Conjugates Contract Manufacturing Market

18.1. France Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antibody Drug Conjugates Contract Manufacturing Market

19.1. Italy Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antibody Drug Conjugates Contract Manufacturing Market

20.1. Spain Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antibody Drug Conjugates Contract Manufacturing Market

21.1. Eastern Europe Antibody Drug Conjugates Contract Manufacturing Market Overview
21.2. Eastern Europe Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antibody Drug Conjugates Contract Manufacturing Market

22.1. Russia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antibody Drug Conjugates Contract Manufacturing Market

23.1. North America Antibody Drug Conjugates Contract Manufacturing Market Overview
23.2. North America Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antibody Drug Conjugates Contract Manufacturing Market

24.1. USA Antibody Drug Conjugates Contract Manufacturing Market Overview
24.2. USA Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antibody Drug Conjugates Contract Manufacturing Market

25.1. Canada Antibody Drug Conjugates Contract Manufacturing Market Overview
25.2. Canada Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antibody Drug Conjugates Contract Manufacturing Market

26.1. South America Antibody Drug Conjugates Contract Manufacturing Market Overview
26.2. South America Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antibody Drug Conjugates Contract Manufacturing Market

27.1. Brazil Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antibody Drug Conjugates Contract Manufacturing Market

28.1. Middle East Antibody Drug Conjugates Contract Manufacturing Market Overview
28.2. Middle East Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antibody Drug Conjugates Contract Manufacturing Market

29.1. Africa Antibody Drug Conjugates Contract Manufacturing Market Overview
29.2. Africa Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antibody Drug Conjugates Contract Manufacturing Market Competitive Landscape And Company Profiles

30.1. Antibody Drug Conjugates Contract Manufacturing Market Competitive Landscape
30.2. Antibody Drug Conjugates Contract Manufacturing Market Company Profiles
- 30.2.1. AbbVie Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Eli Lilly and Company
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Gilead Sciences Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Merck KGaA
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Boehringer Ingelheim
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Antibody Drug Conjugates Contract Manufacturing Market Other Major And Innovative Companies

31.1. Recipharm AB
31.2. Sigma-Aldrich
31.3. Sartorius AG
31.4. Curia
31.5. Lonza Group AG
31.6. Catalent Inc.
31.7. KBI Biopharma
31.8. Alcami Corporation
31.9. Formosa Laboratories
31.10. BioVectra Inc.
31.11. Axplora
31.12. Abzena PLC
31.13. ImmunoGen Inc.
31.14. EirGenix Inc.
31.15. Avid Bioservices Inc.

32. Global Antibody Drug Conjugates Contract Manufacturing Market Competitive Benchmarking

33. Global Antibody Drug Conjugates Contract Manufacturing Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Antibody Drug Conjugates Contract Manufacturing Market

35. Antibody Drug Conjugates Contract Manufacturing Market Future Outlook and Potential Analysis

35.1 Antibody Drug Conjugates Contract Manufacturing Market In 2028 - Countries Offering Most New Opportunities
35.2 Antibody Drug Conjugates Contract Manufacturing Market In 2028 - Segments Offering Most New Opportunities
35.3 Antibody Drug Conjugates Contract Manufacturing Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer